挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

印度Nicholas Piramal India Limited 
Nicholas Piramal印度有限公司（印度Mumbia）的委托生產部門NPIL Pharma公司在2005年收購了Avecia制藥公司，正在試圖發展成為最大的三家委托合成公司之一。

對于NPIL Pharma 公司來說2006年最優先要走做的事情是在完成早先進行的收購后將Avecia公司的委托化學合成和藥物生產服務業務整合進來。通過這次收購，NPIL Pharma公司獲得三個商業部門：1、早期交付小組，位于英國Huddersfield，致力于I期和II期臨床試驗產品的委托合成；2、藥物產品部門，位于英國的Huddersfield和Billingham，致力于擴大并生產后期中間體和API，用于III期臨床試驗和產品上市銷售；3、高效底物部門，位于蘇格蘭的Grangemouth，致力于研發、擴大和生產高效前列腺素和細胞毒API。NPIL Pharma做為收購Avecia公司的一部分，公司還擁有了Avecia公司的子公司Torcan Chemical公司，該公司位于加拿大安大略Aurora，致力于臨床前和早期臨床試驗產品開發。同時，公司還獲得了Reaxa公司（英國曼徹斯特，）25％的股票，該公司致力于催化技術，也創立于Avecia公司。

Avecia公司的資產將被整合進NPIL Pharma公司的資產中，NPIL Pharma公司在印度擁有4個生產部門，包括Mumbai和Chennai的研發實驗室，Chennai的GMP車間，Hyderabad的大規模車間。

收購Avecia公司是NPIL公司在委托合成領域內的第一個收購行為，NPIL Pharma公司現在正在向全球大型委托合成企業方向邁出一大步，成為少數幾個將API/中間體開發和生產整合到一起形成最終劑型藥物的委托生產企業中的一個。

NPIL Pharma公司是Nicholas Piraml印度有限公司的一部分，Nicholas Piraml印度有限公司是印度第四大制藥保健公司，2005年收入達到2億9100萬美元。

Nicholas Piramal India Limited is one of India's largest companies with an unmatched record of managing JVs/Alliances/Partnerships, and a proven commitment to IPR. With strong brand management and sales capabilities, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class, accredited Clinical Research Organisation, NPIL is poised to emerge as India's pharma powerhouse.

With growth fuelled through a strategy of partnerships, quality acquisitions, brand building, focused selling and manufacturing, NPIL's consolidated net sales turnover was US$ 313 million (INR 14.1 billion) in 2005-06 (April to March)".

NPIL has emerged among the leaders in Indian pharma with a unique mix of inorganic and organic growth fuelled through a strategy of acquisitions, brand building and focused selling, and manufacturing. The company has one of the widest product portfolios in India, spanning nine key therapeutic areas, including the Cardio-vascular, Neuro-psychiatry, Oncology, Diabetes Management, Respiratory, Anti-infectives, Gastro-intestinals, Dermatology and NSAIDS.

The company was formed when the Piramal Group acquired Nicholas Laboratories, a small formulations company in 1988 from Sara Lee. It has followed a multi-pronged strategy to integrate and maximize synergies with the planned acquisitions and develop and consolidate its major strength in marketing to therapeutic niches.

Managed by a team of highly proficient industry professionals, NPIL's key strengths come from its strong brand building, selling and distribution, manufacturing and alliance/partnership management skills. The last, especially, are quite unique in the Indian context - few Indian Pharmaceutical have exhibited such a strong and consistent record in successfully and ethically managing JVs/Alliances and Partnerships as NPIL has.

Its policy of respecting IPR and managing partnerships, in keeping with both the letter and the spirit of written agreements, has been widely respected and commended by its partners.

NPIL is the flagship company of the Rs. 2500 crore (US $ 550 million) Piramal Enterprises (PEL), one of India's largest diversified business houses.